Nordic Nanovector has signed a three-year collaborative research agreement with Affibody to develop new advanced radio-immunotherapies (RIT) for multiple myeloma.
Supported by a grant from Eurostars, the project will aggregate Affibody’s proprietary platforms with Nordic’s radio-immunotherapy technology.
The partnership has received approximately €1m from Swedish company Vinnova and the Norwegian Research Council.
Nordic Nanovector CEO Luigi Costa said: "The collaboration with Affibody will allow Nordic Nanovector to expand its product pipeline, while at the same time retaining full focus on the clinical development and commercialisation of our lead product candidate, Betalutin.
"This collaboration serves as an example of how the company intends to leverage its proprietary targeting technology to treat other haematological cancers in need of novel therapeutic approaches."
The project has been designed to provide necessary documentation to commence GMP manufacturing of the Affibody-based RIT, and subsequently start clinical trials.
Nordic will be able to license the global rights to the Affibody-based RIT, upon the successful conclusion of the collaboration.
According to Nordic, the development of an Affibody-RIT will be carried out in parallel with its lead product candidate, Betalutin, for non-Hodgkin Lymphoma treatment.
Affibody CEO David Bejker said: "The Eurostars platform offers an excellent way for two companies with complementary technologies to collaborate and bring novel therapeutics to market, and for Affibody, this comes on top of a year of increased uptake for our platform."
Image: Bone marrow aspirate showing the histologic correlate of multiple myeloma under the microscope. Photo: courtesy of KGH.
